Quick Answer
Arcutis Biotherapeutics, Inc. reported Stockholders Equity of $189.48 million for fiscal year 2025.
Arcutis Biotherapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $189.48M | +20.3% |
| 2024 | $157.54M | +77.7% |
| 2023 | $88.67M | -57.7% |
| 2022 | $209.58M | -29.6% |
| 2021 | $297.68M | +10.0% |
| 2020 | $270.62M | +516.2% |
| 2019 | -$65.03M | -171.1% |
| 2018 | -$23.99M | -380.4% |
| 2017 | -$4.99M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $158.07M | +0.9% | +13.7% |
| June 30, 2025 | $138.97M | -25.5% | -2.6% |
| March 31, 2025 | $142.66M | -36.6% | -9.4% |
| December 31, 2024 | $157.54M | +77.7% | +0.6% |
| September 30, 2024 | $156.64M | +235.3% | -16.0% |
| June 30, 2024 | $186.43M | +131.6% | -17.1% |
| March 31, 2024 | $224.94M | +61.0% | +153.7% |
| December 31, 2023 | $88.67M | -57.7% | +89.8% |
- Arcutis Biotherapeutics, Inc. showed an increase of +20.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2017–2025 period, Arcutis Biotherapeutics, Inc.’s stockholders equity has grown by 3894.9% (from -$4.99 million to $189.48 million).
- The most recent figure is from Arcutis Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: